| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1040938178 |
| P356 | DOI | 10.1038/SJ.BMT.1705160 |
| P698 | PubMed publication ID | 16184183 |
| P5875 | ResearchGate publication ID | 7580434 |
| P50 | author | Alois Gratwohl | Q19859713 |
| Jakob R. Passweg | Q67905482 | ||
| P2093 | author name string | Tichelli A | |
| Martinez MT | |||
| Heim D | |||
| Tsakiris DA | |||
| Buser A | |||
| Stussi G | |||
| Bucher Ch | |||
| P2860 | cites work | Fatal thrombotic thrombocytopenic purpura as a rare complication following allogeneic stem cell transplantation | Q33334788 |
| Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation | Q33335309 | ||
| Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes | Q33337015 | ||
| The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. | Q33337105 | ||
| Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases | Q33338830 | ||
| Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome following allogeneic bone marrow transplantation | Q33342975 | ||
| von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome | Q33343310 | ||
| Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). | Q33343954 | ||
| Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver | Q33344003 | ||
| Transplantation-associated thrombotic microangiopathy: twenty-two years later | Q33345369 | ||
| Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients | Q33345455 | ||
| ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients | Q33346954 | ||
| Clostridium difficile colitis associated with hemolytic-uremic syndrome. | Q33348240 | ||
| Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma | Q33359551 | ||
| Simplified assay for VWF cleaving protease (ADAMTS13) activity and inhibitor in plasma | Q33361473 | ||
| Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion | Q33364155 | ||
| Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support | Q33495752 | ||
| Hemolytic uremic syndrome after allogeneic or autologous hematopoietic stem cell transplantation for childhood malignancies | Q33501821 | ||
| Coagulation abnormalities and thrombotic microangiopathy following bone marrow transplantation from HLA-matched unrelated donors in patients with hematological malignancies | Q33502583 | ||
| Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis | Q33503480 | ||
| von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome | Q33504463 | ||
| Circulating endothelial cells: realities and promises in vascular disorders | Q36030562 | ||
| Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation | Q43790464 | ||
| Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A. | Q44272977 | ||
| Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced | Q44943026 | ||
| Serum levels of soluble adhesion molecules in stem cell transplantation-related complications. | Q52133094 | ||
| Thrombotic Microangiopathies | Q56286857 | ||
| Management of thrombotic microangiopathy following allogeneic transplantation: what is the role of plasma exchange? | Q73670154 | ||
| Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease | Q74372364 | ||
| Diagnostic value of hemostatic parameters in bone marrow transplant-associated thrombotic microangiopathy | Q74523446 | ||
| Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO) | Q78094076 | ||
| Thrombotic microangiopathy following allogeneic bone marrow transplantation | Q78151962 | ||
| Thrombotic microangiopathy after allogeneic bone marrow transplantation: a pathologic abnormality associated with diverse clinical syndromes | Q80111836 | ||
| Hemostatic abnormalities and changes following bone marrow transplantation | Q80890318 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | stem cell transplantation | Q65592366 |
| P304 | page(s) | 993-1000 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants | |
| P478 | volume | 36 |
| Q26992169 | A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury |
| Q36578386 | ABO-histo blood group incompatibility in hematopoietic stem cell and solid organ transplantation |
| Q26738984 | Cancer-associated thrombotic microangiopathy |
| Q41923053 | Central nervous system complications after allogeneic hematopoietic stem cell transplantation |
| Q58553367 | Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT |
| Q48018119 | Clinical dissection of thrombotic microangiopathy |
| Q28067041 | Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome |
| Q80525543 | Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation |
| Q50622232 | Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. |
| Q33375739 | Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? |
| Q33425079 | Eculizumab in Transplant-Associated Thrombotic Microangiopathy. |
| Q52875784 | Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. |
| Q33393944 | Evaluation of schistocyte monitoring after haematopoietic stem cell transplantation |
| Q33424902 | Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy |
| Q41992358 | Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies. |
| Q33417613 | Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options |
| Q62029355 | High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease |
| Q48919593 | Histoblood groups other than HLA in organ transplantation |
| Q90776320 | Histologic features of hematopoietic stem cell transplant-associated thrombotic microangiopathy are best percepted in deep skin biopsies and renal biopsies, while showing a significant overlap with changes related to severe acute graft-versus-host d |
| Q33398214 | ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes |
| Q50466984 | Impact of recipient ABH secretor status on outcome in minor ABO-incompatible hematopoietic stem cell transplantation. |
| Q89987658 | Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy |
| Q38806679 | Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy? |
| Q33384578 | Posttransplant thrombotic microangiopathy: sensitivity of proposed new diagnostic criteria |
| Q42200268 | Renal and neurological response with eculizumab in a patient with transplant associated thrombotic microangiopathy after allogeneic hematopoietic progenitor cell transplantation |
| Q33382787 | Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis |
| Q92092550 | Severe, persistent neurotoxicity after transplant-associated thrombotic microangiopathy in a pediatric patient despite treatment with eculizumab |
| Q40709615 | The Use of Hyperbaric Oxygen Therapy in the Treatment of Non-healing Ulcers Secondary to Graft-versus-host Disease. |
| Q38287610 | Therapeutic apheresis for patients with cancer |
| Q33398627 | Third-party mesenchymal stromal cell infusion is associated with a decrease in thrombotic microangiopathy symptoms observed post-hematopoietic stem cell transplantation. |
| Q49375853 | Thrombotic microangiopathy following haematopoietic stem cell transplant |
| Q35098992 | Thrombotic microangiopathy in haematopoietic cell transplantation: an update |
| Q33383355 | Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment |
| Q48346280 | Thrombotic microangiopathy with concomitant GI aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome. |
| Q92798609 | Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal |
| Q30235311 | Transplant-associated thrombotic microangiopathy: opening Pandora's box. |
| Q33386308 | Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange |
| Q33428744 | Treatment of thrombotic microangiopathy after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin |
| Q42910482 | Vascular Endothelium Changes After Conditioning in Hematopoietic Stem Cell Transplantation: Role of Cyclophosphamide and Busulfan |
Search more.